Literature DB >> 17019193

Ischemia reperfusion injury, preconditioning and critical illness.

Peter Rock1, Zhenhai Yao.   

Abstract

The purpose of this review is to describe in more detail ischemia reperfusion injury and preconditioning, and to speculate on the potential role of preconditioning in the care of critically ill patients. Current hemodynamic treatment of hypotension and hypoperfusion in critically ill patients is directed at ensuring essential organ perfusion by maintaining intravascular volume and cardiac output, and ensuring adequate oxygen delivery by maintaining arterial oxygen partial pressure and hemoglobin levels. However, morbidity and mortality remain high and new approaches to critically ill patients are required. Treatments are needed that can protect against organ ischemia during periods of low blood flow. In recent years, there has been a growing appreciation of the importance of ischemia reperfusion injury. Ischemia associated with reperfusion may result in greater injury than ischemia alone. Ischemic preconditioning is used to describe the protective effect of short periods of ischemia to an organ or tissue against longer periods of ischemia. Although first described in the myocardium, there is now evidence that this phenomenon occurs in a wide variety of organs and tissues, including the brain and other nervous tissue such as the retina and spinal cord, liver, stomach, intestines, kidney, and the lungs. Preconditioning therapy may offer a new avenue of treatment in critically ill patients. Both traditional preconditioning methods and pharmacologic agents that mimic or induce such preconditioning may be used in the future. Clinical trials of pharmacologic agents are underway in patients with coronary artery disease. Further trials of such methods and agents are needed in critically ill patients suffering from sepsis or multiorgan system failure.

Entities:  

Year:  2002        PMID: 17019193     DOI: 10.1097/00001503-200204000-00001

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  6 in total

1.  Ischemia as a possible effect of increased intra-abdominal pressure on central nervous system cytokines, lactate and perfusion pressures.

Authors:  Athanasios Marinis; Eriphili Argyra; Pavlos Lykoudis; Paraskevas Brestas; Kassiani Theodoraki; Georgios Polymeneas; Efstathios Boviatsis; Dionysios Voros
Journal:  Crit Care       Date:  2010-03-15       Impact factor: 9.097

2.  Protective effects of caffeic acid phenethyl ester on intestinal ischemia-reperfusion injury.

Authors:  Yuksel Yildiz; Mukadder Serter; Rauf Onur Ek; Kemal Ergin; Serpil Cecen; Ece Mine Demir; Cigdem Yenisey
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

3.  GDNF is involved in the barrier-inducing effect of enteric glial cells on intestinal epithelial cells under acute ischemia reperfusion stimulation.

Authors:  Weidong Xiao; Wensheng Wang; Wei Chen; Lihua Sun; Xiangsheng Li; Chaojun Zhang; Hua Yang
Journal:  Mol Neurobiol       Date:  2014-05-31       Impact factor: 5.590

4.  Renalase contributes to the renal protection of delayed ischaemic preconditioning via the regulation of hypoxia-inducible factor-1α.

Authors:  Feng Wang; Guangyuan Zhang; Tao Xing; Zeyuan Lu; Junhui Li; Cheng Peng; Guohua Liu; Niansong Wang
Journal:  J Cell Mol Med       Date:  2015-03-17       Impact factor: 5.310

5.  Ischemic preconditioning attenuates lipid peroxidation and apoptosis in the cecal ligation and puncture model of sepsis.

Authors:  Cimen Gülben Olguner; Uğur Koca; Emel Altekin; Bekir Uğur Ergür; Seden Duru; Pelin Girgin; Aydin Taşdöğen; Kerim Gündüz; Seda Güzeldağ; Muhammed Akkuş; Serap Cilaker Micili
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

6.  Perspective: Drawing on Findings From Critical Illness to Explain Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Dominic Stanculescu; Jonas Bergquist
Journal:  Front Med (Lausanne)       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.